Rodman ups Alnylam price target to $19

Rodman & Renshaw has raised its year-end price target for “market outperform-rated” Alnylam Pharmaceuticals (NASDAQ:ALNY) to $19 from $12, based on changes to the company’s business model and a sum-of-the-parts analysis. Noting that Alnylam has made considerable progress in its clinical development programs in the past six months, analyst Michael King writes that he has [...]

Rodman to launch automated electronic transaction platform

Rodman & Renshaw Capital Group (NASDAQ:RODM), via a new subsidiary, DirectMarkets, has unveiled an automated, state-of-the-art electronic transaction platform to directly link existing public company issuers and investors seeking to transact primary offerings of securities. Both investors and issuers will benefit from 24/7 seamless access to DirectMarkets’ platform through a graphical user interface accessible via computer [...]

Rodman sees Neoprobe driving shareholder value

In a new report, Rodman & Renshaw reports on a management meeting with Neoprobe (NASDAQ:NEOP) on Wednesday, when it obtained an update of upcoming events that could “significantly drive shareholder value going forward.” The FDA recently accepted a NDA from Neoprobe for the use of its Lymphoseek treatment in intraoperative lymphatic mapping, and provided Lymphoseek [...]

Rodman starts Celsion at market outperform

Rodman & Renshaw has initiated coverage of Celsion (NASDAQ:CLSN) with a “market outperform/speculative risk” rating and a target price of $6, based on a discounted revenues and earnings per share valuation methodology. The stock closed at $2.75 on Tuesday. “With approximately $25 million in cash pro forma, and an enterprise value of $47 million, we [...]

Rodman sees higher small-cap biotech valuations

Citing the proposed acquisition of Anadys Pharmaceuticals (NASDAQ:ANDS) by Roche (NASDAQ: RHHBY) at a 260% premium, Rodman & Renshaw figures that Pharma’s strong balance sheet and expiring patents on blockbuster drugs “bring together the perfect storm of factors could lead to higher small-cap biotechnology valuations.” The Roche-Anadys acquisition highlights the “increasing appetite of pharmaceutical companies [...]

Rodman starts GTX at market outperform

Rodman & Renshaw has initiated coverage of GTX (NASDAQ:GTXI) with a “market outperform, speculative risk” rating and 12-month price target of $7, saying the company “could potentially be the next great play in prostate cancer.” The stock, which closed at $3.34 on Thursday, is “our highest-conviction name in the small-cap biotech space, offering investors a [...]

Rodman starts Alnylam at market outperform

Rodman & Renshaw has initiated coverage of one-time market darling Alnylam Pharmaceuticals (NASDAQ:ALNY) with a “market outperform, speculative risk” rating and 12-month price target of $12. The stock closed at $7.13 yesterday. “It is our view that the shares have been overly punished by investors and the pendulum of sentiment has swung so far that [...]

In conversation with Michael King and Elemer Piros

Rodman & Renshaw’s 13th Annual Healthcare Conference last week was another roaring success. Held in conjunction with Rodman’s Annual Global Investment Conference, total attendees reached some 4,000, with 400 presenting companies from the healthcare, mining, energy, financial services and clean technology sectors, Israel and China. In this exclusive interview with BioTuesdays.com, two of Rodman’s managing [...]

Rodman sees potential approval of ColonSentry in fourth quarter

In a meeting last week at the Rodman & Renshaw conference with Enzo Biochem (NYSE:ENZ), analyst Yigal Nochomovitz came away with an impression that feedback from New York State regulators “has been favorable” for Enzo’s bid to obtain approval for the GeneNews (TSX:GEN) ColonSentry molecular diagnostic test for assessing a patient’s current risk of having [...]

Rodman starts Biolase at market outperform

Rodman & Renshaw has initiated coverage of Biolase Technology (NASDAQ:BLTI) with a “market outperform” rating and 12-month price target of $6, representing about 2.5 times estimated sales of $73 million in 2012. The stock closed at $3.53 on Thursday. Biolase is the leader in the dental laser surgery space, with an 80% market share in [...]

Next Page »